Efudix

Quick links to important sections

Efudix

Method of action: Antitumour, Cytostatic

Treatment option: Cancer

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Efudix

What is Efudix?

Efudix is a topical cream containing the active ingredient fluorouracil, which belongs to a group of medicines known as antimetabolites. Unlike systemic treatments, this cream is applied directly to the skin to target specific areas of concern.

How it Works

The active substance, fluorouracil, interferes with the production of DNA and RNA within cells. Because abnormal or precancerous cells typically grow and divide more rapidly than healthy skin cells, they absorb the medication more readily. By disrupting the growth process of these atypical cells, the treatment helps to eliminate them while allowing healthy skin to regenerate in the treated area.

Therapeutic Use

Efudix is primarily used for the treatment of various non-melanoma skin conditions. It is frequently prescribed for:

  • Actinic Keratosis: Also known as solar keratosis, these are rough, scaly patches on the skin caused by years of sun exposure. They are considered precancerous because, if left untreated, they have the potential to develop into skin cancer.
  • Bowen's Disease: A very early form of skin cancer where the abnormal cells are confined to the outermost layer of the skin (the epidermis).

By treating these conditions, the medication aims to clear damaged skin cells before they can progress into more invasive forms of skin cancer.

Regulatory References

  1. MedlinePlus

What side effects are possible with Efudix?

Possible Side Effects and Safety Information

The safety profile of topical Fluorouracil (Efudix) is principally defined by predictable local skin reactions, with specific constraints regarding systemic risk and use in special populations, according to official regulatory documentation.


Frequency and Organ Systems

Adverse effects are categorized by frequency, with the most common being localized to the application site (Skin and Subcutaneous Tissue Disorders).

Frequency Classification Key Adverse Reactions (System-Organ Classes)
Very Common / Common Application Site Reactions (Erythema, scaling, crusting, pain, pruritus, inflammation, oedema).
Uncommon Infections (Impetigo), Nervous System (Insomnia), Eye Disorders (Periorbital oedema, increased lacrimation), Gastrointestinal Disorders (Nausea).
Very Rare Severe Systemic Toxicity, Haematological Disorders (Pancytopenia, Neutropenia), Severe Hypersensitivity Reactions.

Serious Adverse Reactions and Restrictions

Regulatory documents highlight the risk of severe, life-threatening Systemic Toxicity, particularly in individuals with a deficiency of the Dihydropyrimidine Dehydrogenase (DPD) enzyme. This condition increases the body's exposure to Fluorouracil. Rare cases of Haematological Disorders (e.g., bone marrow suppression) and severe allergic reactions are also documented.

Population-Specific Constraints

Use is Contraindicated in Pregnancy due to the documented risk of fetal harm. For Lactation, a determination must be made to discontinue either the drug or breastfeeding. Additionally, patients should avoid Ultraviolet (UV) Radiation exposure, as this may intensify the local inflammatory reaction. Treatment intervals must be maintained when co-administering with certain antiviral nucleoside analogues to mitigate toxicity risk.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

Feature Official Regulatory Statements
Documented overdose presentations Characterized by severe signs of systemic toxicity, including nausea, vomiting, diarrhea, and stomatitis (oral inflammation).
Physiological systems affected Hematological system (myelosuppression), Gastrointestinal system (ulceration, bleeding), Cardiovascular system (cardiotoxicity, arrhythmias), and Central Nervous System (ataxia).
Exposure-related factors Systemic toxicity and overdose risk are associated with accidental ingestion or extensive percutaneous absorption (topical use on large or damaged areas).
Population-specific overdose notes Individuals with Dihydropyrimidine Dehydrogenase (DPD) deficiency have a significantly increased, potentially fatal risk of systemic toxicity from Fluorouracil exposure.
Emergency-response statements Management is defined as symptomatic and supportive, and no specific antidote is known for Fluorouracil intoxication documented in official labeling.
When immediate medical help is required Immediate medical attention must be sought in the event of accidental ingestion or suspected systemic overdose. Hospital monitoring and frequent laboratory tests, including daily blood counts, are required.

The official overdose profile is structured around the immediate requirement to seek emergency medical help if signs of severe systemic toxicity are suspected, such as significant gastrointestinal or neurological signs. This action is necessary due to the high-risk potential for delayed, life-threatening consequences, particularly severe myelosuppression, and the fact that management is limited to supportive care as no specific antidote is known.

Therapeutic Uses of Efudix

What Efudix Treats: Main Uses and Benefits

Efudix (topical Fluorouracil) is applied across domains where additional symptomatic support is needed and is considered relevant in clinical contexts that involve acute or unstable symptom patterns.

This medication is commonly used to help treat actinic or solar keratoses, which are pre-cancerous lesions, and certain low-grade forms of skin cancer, such as superficial basal cell carcinoma.


Therapeutic Focus and Symptom Relief

This medication is generally used to help address rough, scaly patches or crusted spots on chronically sun-exposed skin. The therapeutic benefit may include the management of these pre-cancerous lesions, and it may assist in managing the risk associated with their potential for progression. It is relevant for easing the symptomatic burden of conditions like Bowen's Disease, and it is also commonly used for scenarios involving multiple lesions or widespread abnormalities across broad areas of sun-damaged skin (field cancerization). This supportive relief contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“The primary benefit is the management of pre-cancerous and superficial malignant lesions, which contributes to improving comfort during periods of heightened symptoms.”


Quick Fact: Contextual Note on Symptom Management

Efudix is commonly used to help manage symptoms related to physical discomfort in patients who present with sun-related skin conditions where symptomatic assistance is needed.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Efudix

Eligibility scope Official Regulatory Status
Populations for whom use is contraindicated Pregnant women, nursing mothers, and patients with DPD enzyme deficiency.
Age-related eligibility Not recommended for the pediatric population (children and adolescents). Use is permitted for adults and older adults, with no special precautions required for the latter.
Condition-specific eligibility Contraindicated in patients with known hypersensitivity to the active ingredient or any component of the cream.
Eligibility-related restrictions Women of childbearing potential must use effective contraceptive measures during treatment and for 6 months post-treatment. Men are recommended to use contraception for 3 months post-treatment.

Connection to the overall eligibility profile

The official regulatory documents strictly define who can and cannot use Efudix (topical Fluorouracil) by establishing absolute contraindications across specific population groups. The medicine is contraindicated due to the potential for severe harm in pregnant and breastfeeding women, and in patients with DPD enzyme deficiency, where it carries a risk of life-threatening systemic toxicity. Furthermore, use is not recommended for the pediatric population because safety and effectiveness have not been established. The restrictions also mandate the use of effective contraception for all patients of reproductive potential throughout the defined periods of treatment and recovery.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of topical Fluorouracil primarily through its reliance on the Dihydropyrimidine Dehydrogenase (DPD) enzyme for clearance from the body. This reliance dictates strict constraints on co-administration with other substances.

Contraindicated Combinations

Co-administration with specific antiviral nucleoside analogues, notably Brivudine and Sorivudine, is formally contraindicated. These substances are potent inhibitors of the DPD enzyme, and their simultaneous use is documented to lead to a substantial increase in plasma levels of fluorouracil.

Regulatory Constraints

Constraint Category Official Regulatory Statement
Timing Separation A minimum separation interval of at least four weeks is required between treatment with Brivudine, Sorivudine, or their analogues and the administration of Fluorouracil.
Exposure Modification DPD enzyme inhibition results in reduced clearance, which may lead to systemic toxicity from increased exposure.
Population-Specific Note Dihydropyrimidine Dehydrogenase (DPD) enzyme deficiency is cited as a contraindication due to the high risk of life-threatening systemic toxicity.
Photodynamic Effect Exposure to Ultraviolet (UV) rays or sunlight should be minimized during and immediately following treatment, as the intensity of the localized reaction may be increased.

No mandatory restrictions or contraindications regarding interactions with food, alcohol, or herbal products are explicitly documented in the official regulatory labels for the topical formulation.

Mechanism of Action

The mechanism of action for Efudix (Fluorouracil) is defined by its selective ability to disrupt fundamental cellular processes, primarily targeting cells that are rapidly multiplying.

Targeted Blockade of DNA Precursor Synthesis

The core mechanistic domain describes the function of the drug as a pyrimidine antimetabolite. This involves the active metabolite FdUMP acting as a mechanism-based inhibitor of the enzyme Thymidylate Synthase ( TS). This action starves the hyperproliferative cells of a key building block ( dTMP) needed for DNA synthesis, leading to thymineless death and selective cellular destruction at the application site.

Disruption of Genetic and Protein Machinery

This domain describes the secondary action where Fluorouracil is misincorporated into the cell's RNA and, to a lesser extent, DNA. This process creates 'fraudulent' genetic material, which further impairs essential processes like protein synthesis and cell maintenance. This dual genetic and enzymatic interference compounds the damage, initiating the localized cytotoxic cascade.

Initiation of Selective Tissue Erosion

This physiological domain details how the molecular actions translate into a visible result. The targeted cell death and subsequent localized inflammation produce a predictable sequence of erosion and necrosis in the abnormal tissue. This mechanism results in the physiological process of epithelisation, where cellular regeneration replaces the destroyed tissue layer.

Dosage and Administration Information

The administration of Efudix (topical Fluorouracil) is defined by established guidelines to ensure appropriate localized application of the cytotoxic agent.


Administration Scope

Feature Description
Route of administration Topical application only, directly to the affected skin area.
Dosing schedule A thin film of the 5% cream or solution is applied for Superficial Basal Cell Carcinoma and Actinic Keratosis. Regional formulations may include a 0.5% cream.
Frequency and Timing Application is typically performed once or twice daily, as directed by the prescribed regimen.
Age-group rules Use in pediatric patients is generally not recommended due to limited data; no specific dose adjustment is mandated for older adults.

Resulting Procedural Structure

The use protocol requires that application be performed using a glove or non-metal applicator, or by washing hands thoroughly and immediately afterward. Treatment duration for Actinic Keratosis typically lasts two to four weeks, while Superficial Basal Cell Carcinoma may require three to twelve weeks of use. Application is continued until the necessary local tissue reaction, such as erosion or ulceration, is achieved, which serves as the endpoint for stopping the regimen. Furthermore, the total treated surface area should not exceed approximately 500 cm^2 at any given time, according to established parameters.


Connection to the overall use protocol

The overall protocol enforces a highly structured, topical regimen with strict constraints on frequency, duration, and treated area. These instructions establish how the medicine is applied and how long the application should continue, based on the documented tissue response criteria. Missed doses are managed by skipping the application if it is near the time for the next scheduled dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Topical Fluorouracil (Efudix)

This section describes the types of studies that have been conducted with topical Fluorouracil. Findings reflect group patterns observed in research, not personal outcomes.


The Research Landscape for Topical Fluorouracil

Research on topical Fluorouracil was studied for both Actinic Keratoses (AKs) and Superficial Basal Cell Carcinoma (sBCC). For AKs, the evidence includes Randomized Controlled Trials (RCTs) and Systematic Reviews. For sBCC, the research includes RCTs, but also single-arm studies.

The studies primarily focus on measuring lesion assessment (the disappearance of the abnormal spots) or tissue sample assessment (the absence of abnormal cells on biopsy) over defined time intervals. These research settings were used in studies examining how symptoms change over time and to monitor physiological states related to the conditions studied.


Research Examining Actinic/Solar Keratoses (AK)

This part will summarize the available evidence for Actinic Keratoses (AKs), which are rough, scaly patches on sun-exposed skin that have been a focus of regulatory study.

What Researchers Studied

These studies have primarily focused on populations of immunocompetent adults who have multiple lesions. The main outcomes researchers monitored include the measurement of complete assessment of lesions in the treated area and the mean percentage change in the count of lesions from baseline. Evaluations are typically conducted right after the application period and then followed up over short-term intervals of a few months.

What the Studies Reported (Neutral Summary)

Studies reported measurements of both complete and partial lesion assessment in the observed populations during and after the treatment interval. Research also described patterns where local skin reactions measured during the study period was observed to be associated with the subsequent measurements of lesions.


Research Examining Superficial Basal Cell Carcinoma (sBCC)

This block describes the research exploring the use of topical Fluorouracil for Superficial Basal Cell Carcinoma (sBCC), which is a low-grade form of skin cancer.

What Researchers Studied

Research includes single-arm studies where the cream was observed in patients with a confirmed diagnosis of sBCC. The core outcomes studied were the assessment of tissue samples and the recurrence rate (tracking if the tumor returned) over several years. Study populations generally consisted of adults with low-risk sBCC lesions.

What Remains Uncertain

There is a recognized need for more prospective, long-term, randomized comparisons against all established surgical and non-surgical treatments for sBCC. Some data on recurrence for sBCC is derived from studies where evidence certainty may vary across studies. Furthermore, research exploring short-term symptom changes does not determine whether an individual will respond similarly; study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Topical Fluorouracil Shows Long-term Benefit for Actinic Keratoses (VAKCC Trial - Long-term follow-up)
  2. Fluorouracil (Topical) - NCI (National Cancer Institute) Overview (Covers Indications: AK and sBCC)
  3. Fluorouracil - StatPearls (NCBI Bookshelf) (Covers General Use, Specific Patient Populations, and DPD deficiency context)

Frequently Asked Questions (FAQ)

Common questions about Efudix (FAQ)

Q: What is the difference between Efudix and fluorouracil?

A: The difference is that Fluorouracil (mathbf5-FU) is the name of the active ingredient and the chemical compound in the medicine. Efudix is a mathbfbrand name for a specific topical cream or solution formulation that contains fluorouracil. The official product information classifies the drug by its chemical name, Fluorouracil.

Q: Will I see results from Efudix right away?

A: The full effect of the treatment takes time and is a gradual process that involves local tissue reaction. Official product information indicates that the first visible sign, which is usually redness (mathbferythema), typically appears within mathbf3 to mathbf5 days after starting application. More intense reactions, such as blistering or peeling, may develop over the following weeks.

Q: Can Efudix cream be used on the face?

A: Yes, the topical cream is commonly used to treat affected areas on the face. Official guidelines state to avoid letting the cream build up in folds around the eyes, nose, or mouth.

Q: Are there any areas of the body where Efudix should not be applied?

A: Regulatory information indicates that the cream is not intended for use on areas where it may contact mucous membranes. This includes sensitive areas like the inside of the mathbfnostrils, the mathbflips, and the mathbfeyes.

Q: What does official research say about Efudix for Bowen's disease?

A: Official documents indicate that topical Fluorouracil cream is mathbflisted as a topical treatment for mathbfBowen's disease, which is a type of skin cancer known as mathbfSquamous Cell Carcinoma in situ. The primary purpose of the cream is the localized destruction of these abnormal cells.

Q: Can Efudix interact with daily moisturizing lotions?

A: To avoid potential interactions or increased irritation, official patient guides instruct users to avoid applying cosmetics, sunscreens, or moisturizing lotions directly to the area being treated with the cream. Only use topical products if specifically directed by a healthcare provider.

Q: Is there a list of common medications that interact with Efudix?

A: Official literature notes that the drug mathbfFluorouracil is known to have interactions with many other medications, including aspirin and certain NSAIDs. While the topical form has low systemic absorption, the most critical interaction is with medications that inhibit the mathbfDPD enzyme, as this can lead to severe toxicity.

Q: What happens if I accidentally get Efudix in my eye?

A: Regulatory safety information describes a procedure where the eyes are mathbfimmediately and thoroughly flushed with water or a sterile saline solution. This information notes that medical attention may be sought if irritation or discomfort persists after flushing.

Q: Is there a specific period of time after using Efudix before one can be exposed to sunlight?

A: Official safety warnings state that sun exposure mathbfmust be minimized during treatment and immediately afterward, as the local inflammatory reaction can cause severe sun sensitivity. The skin may remain mathbfhighly sensitive for several weeks after the treatment course has been completed.

Q: Do the skin changes caused by Efudix heal completely?

A: Yes, the damaged tissue is typically followed by healing through a process called mathbfre-epithelization (the replacement of destroyed tissue with new, healthy cells). This healing process is generally complete mathbf1 to mathbf2 months after the treatment has concluded, and scarring is not generally expected in the treated area.

Q: How quickly do the side effects of Efudix usually fade after stopping use?

A: The mathbfintense side effects (like redness and inflammation) typically begin to mathbffade within a few weeks after the final application. The full healing of the skin (re-epithelization) may take mathbf1 to mathbf2 months to fully complete.

Q: Can Efudix be used with other medicated skin products?

A: In some specialized regimens, topical mathbfFluorouracil is used in combination with other medicated products to potentially enhance the treatment's effectiveness or shorten the overall duration. However, official guidelines state that combining it with other products should only occur if explicitly directed by their prescriber.

Q: Does the treatment area need a special covering after Efudix is applied?

A: Official patient instructions describe avoiding covering the treated area with any mathbfairtight or occlusive dressing (like a tightly sealed bandage). Using such a covering may intensify the skin reaction, and should only be done if specifically advised by a healthcare provider.

Q: What is the risk of Efudix being absorbed into the body?

A: While the cream is designed for localized action on the skin, regulatory warnings acknowledge there is some systemic absorption of the mathbfFluorouracil into the body. This is why official warnings highlight the mathbflife-threatening risk of toxicity for patients who have a deficiency in the mathbfDPD enzyme.

Q: What is the expected long-term appearance of skin treated with Efudix?

A: The healing process aims to replace the treated abnormal tissue with normal skin tissue. However, in rare instances, particularly after severe inflammatory reactions, mathbfaltered skin pigmentation (discoloration) or mathbfscarring may occur.

Q: What should be done if too much Efudix is accidentally applied?

A: Regulatory-linked safety information states that if the cream is accidentally swallowed or if a mathbfsignificantly large amount is applied to the skin, safety information notes that in these situations, a mathbfpoison control center or mathbfemergency department may be contacted. Applying too much cream can increase the risk of severe side effects like mathbfulceration and mathbfdiscoloration.

Q: Why do some people need repeat treatments with Efudix?

A: Repeat treatment may be necessary if the original treatment course was mathbfincomplete and some abnormal cells remain, or if mathbfnew lesions develop on the skin after the initial treatment area has fully healed. The need for subsequent treatments is based on the reassessment of the skin by a professional.

Q: How does the official literature describe the long-term effectiveness of Efudix?

A: Studies report that a single course of fluorouracil cream was mathbfobserved to reduce the number of lesions and the need for subsequent spot treatments for periods mathbflonger than two years in the populations studied for Actinic Keratosis.

Q: What is the official information regarding driving or operating machinery while using Efudix?

A: Official warnings describe the potential for mathbfdizziness and mathbfmental confusion associated with mathbfFluorouracil. This information is relevant when considering driving or operating machinery, even though topical application minimizes systemic exposure.

Q: Is it necessary to use a different sunscreen while undergoing Efudix treatment?

A: Regulatory-linked patient information notes the importance of using a mathbfbroad-spectrum sunscreen with an mathbfSPF of mathbf30 or higher every day before going outdoors. This sunscreen is often instructed to be mathbfre-applied regularly, in addition to minimizing overall sun exposure.

Q: Does Efudix have known interactions with common over-the-counter pain relievers?

A: Official drug information indicates that mathbfFluorouracil has been associated with mathbfmoderate to mathbfminor interactions with certain common mathbfover-the-counter pain relievers, including mathbfAspirin and other mathbfNSAIDs (Non-Steroidal Anti-Inflammatory Drugs). This information is primarily relevant to the systemic use of the drug.

Q: What is the difference in side effects between using Efudix cream on the body versus the face?

A: Official guidance notes that a mathbflonger treatment duration or mathbfincreased frequency of application may be required for mathbfbody areas outside of the head and neck. This difference in application protocol could potentially lead to a mathbfmore prolonged or intense local reaction on the body compared to the face.

Q: How does Efudix impact the surrounding healthy skin?

A: The mechanism of action is designed to mathbfselectively target abnormal, sun-damaged cells. However, official information notes that the mathbfhealthy skin immediately surrounding the treatment area may still become mathbfreddened as a mathbftemporary reaction during the course of the treatment.

Q: Is Efudix known to cause any permanent skin discoloration?

A: While the skin is expected to heal, official patient information states that following a mathbfsevere local reaction, there is a mathbfsmall risk of mathbfaltered skin pigmentation (discoloration) or mathbfscarring. This risk is particularly noted in areas such as the lower legs.

Q: Can people with a history of heart disease use Efudix?

A: Regulatory precautions associated with mathbfFluorouracil list pre-existing heart disease (such as mathbfcoronary artery disease) as a mathbfprecaution. This is because the systemic form of the drug is associated with a risk of mathbfcardiotoxicity, and there is some systemic absorption from the topical cream.

How should Efudix be stored and disposed of?

Storing Efudix (Fluorouracil) Cream

Efudix cream must be stored according to regulatory requirements to preserve its stability and maintain safety. The cream must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). Storage areas must be away from heat, moisture, and direct light.

Key Storage Constraints

  • Freezing: The product must not be refrigerated or frozen.
  • Container: The tube must be kept tightly closed when not in use.
  • In-Use Stability: After the tube is opened for the first time, the cream must be used within 90 days.
  • Safety: The medication is required to be stored out of reach of children and pets.

Disposal of Efudix

Due to its classification, unused or expired Efudix must be handled as hazardous medicinal product waste. Disposal must occur in accordance with local and national regulations. The cream should not be discarded into household trash or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Efudix found in:

A-Z Index: